Alkaloids Reported in the Genus Griffinia (Amaryllidaceae): Phytochemical Evidence and Current Limitations in Anticancer Interpretation

Natural products continue to provide pharmacologically relevant scaffolds for anticancer drug discovery, with alkaloids from the Amaryllidaceae family among the most structurally diverse and biologically investigated classes of plant secondary metabolites. Within this family, the Brazilian genus Griffinia—comprising approximately 21 species predominantly endemic to the Atlantic Forest and Cerrado—remains substantially underrepresented in the phytochemical and pharmacological literature, with fewer than five species subjected to any level of biological evaluation and no genus-wide mechanistic profile available to date. This critical review specifically examines what the current literature reports regarding the anticancer relevance of Griffinia alkaloids, addressing a gap that has not been systematically investigated in prior Amaryllidaceae reviews. Six structural classes—lycorine-, galanthamine-, crinine-, hemanthamine-, montanine-, and homolycorine-type alkaloids—have been detected in Griffinia species primarily through gas chromatography–mass spectrometry and liquid chromatography–mass spectrometry profiling; however, isolation and direct biological validation have been reported for only one species, Griffinia gardneriana, in which lycorine and related compounds exhibit cytotoxic and genotoxic activities associated with caspase-3-mediated apoptosis. This finding constitutes the sole genus-specific mechanistic anchor currently available. The broader biological literature on Amaryllidaceae alkaloids—encompassing apoptosis induction, cell cycle arrest, redox imbalance, and modulation of phosphoinositide 3-kinase/protein kinase B (PI3K/Akt), nuclear factor kappa B (NF-κB), and mitogen-activated protein kinase (MAPK) signaling—is explicitly used here as contextual evidence for the structural classes detected in Griffinia, not as proof of genus-level activity. This distinction is central to the evidentiary framework of the review and is maintained throughout. Approximately 70% of evaluated Amaryllidaceae species lack comprehensive phytochemical and biological characterization, a limitation that is directly reflected in Griffinia. Future research priorities include rigorous compound isolation and structural elucidation across underexplored species, genus-specific bioactivity testing in well-defined cancer models, and mechanism-oriented studies anchored in direct experimental evidence rather than structural analogies. Semi-synthetic optimization and multi-omic approaches represent longer-term but tractable avenues once the primary pharmacological characterization is established.